Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;8(3):143-59.
doi: 10.1177/1756283X15576462.

From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease

Affiliations
Review

From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease

Charles W Randall et al. Therap Adv Gastroenterol. 2015 May.

Abstract

Crohn's disease (CD) is a debilitating, systemic inflammatory disorder with both gastrointestinal and extraintestinal manifestations. Its existence predates modern medicine, but its precise etiology remains incompletely understood. Most authorities suggest a multifactorial pathogenesis owing to a mixture of genetic disorders, immunologic dysregulation, microbiota disequilibrium and environmental influences. Of these factors, the overactive immunologic response seen in CD appears to be the most promising target of medical therapy. Biological agents comprise a relatively new class of drugs that can induce and maintain remission in moderate to severe CD, as well as in ulcerative colitis. This review will provide an overview of CD, its history, clinical features, pathophysiology, and treatment options focusing on current and future biological agents with an emphasis on drug development, dosage and administration.

Keywords: Crohn’s Disease; Inflammatory Bowel Disease; anti-TNF; biologics.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr. Randall receives research funding, speaking or consulting fees from: Abbvie, UCB, Janssen, Takeda, Salix, Prometheus, Amgen and Bristol-Meyers Squibb.

References

    1. Ananthakrishnan A., Hur C., Korzenik R. (2012) Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn’s disease: results of a decision analysis. Dig Dis Sci 57: 472–480. - PubMed
    1. Andoh A., Yagi Y., Shioya M., Nishida A., Tsujikawa T., Fujiyama Y. (2008) Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 14: 5154. - PMC - PubMed
    1. Ardizzone S., Puttini P., Cassinotti A., Porro G. (2008) Extraintestinal manifestations of inflammatory bowel disease. Digest Liver Dis 40: 253–259. - PubMed
    1. Aufses A., Jr. (2001) The history of Crohn’s disease. Surg Clin N Am 81: 1–11. - PubMed
    1. Bandzar S., Gupta S., Platt M. (2013) Crohn’s disease: a review of treatment options and current research. Cell Immunol 286: 45–52. - PubMed

LinkOut - more resources